Cynosure has announced the U.S. Food and Drug Administration (FDA) clearance of the Potenza™ radiofrequency (RF) microneedling device, the first and only FDA-cleared four-mode RF microneedling device offering clinicians unrivaled versatility and personalized treatments for patients.
Read MoreCynoSure have announced a new partnership programme with training leaders MATA (Medical Aesthetic Training Academy) and the international awarding body CIBTAC (Confederation of International Beauty Therapy and Cosmetology) to...
Read MoreHologic, Inc. announced completion of an agreement between its Cynosure division and Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to...
Read MoreCynosure are proud to announce a host of upcoming educational and commercial activities at the FACE Conference, London (14-16th June 2018). The main activity will be an exclusive commercial workshop (more…)
Read MoreArtificial Intelligence used to erase scarring
Read MoreCynosure, Inc. a leader in laser- and light-based aesthetic treatments, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SculpSure™, the...
Read MoreCynosure and El.En. S.p.A. sign exclusive agreement to market MonaLisa Touch™ in North America for gynecology indications
Read MoreCynosure, Inc., which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months ended September 30, 2014. Third-Quarter 2014 (more…)
Read More
